|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM371906431 |
| 003 |
DE-627 |
| 005 |
20240822232635.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240504s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110232
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1509.xml
|
| 035 |
|
|
|a (DE-627)NLM371906431
|
| 035 |
|
|
|a (NLM)38701960
|
| 035 |
|
|
|a (PII)S1521-6616(24)00341-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Guo, Wei-Yi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Complement system is overactivated in patients with IgA nephropathy after COVID-19
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2024
|
| 500 |
|
|
|a Date Revised 22.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a IgA nephropathy (IgAN), which has been confirmed as a complement mediated autoimmune disease, is also one form of glomerulonephritis associated with COVID-19. Here, we aim to investigate the clinical and immunological characteristics of patients with IgAN after COVID-19. The level of plasma level of C5a (p < 0.001), soluble C5b-9 (p = 0.018), FHR5 (p < 0.001) were all significantly higher in Group CoV (33 patients with renal biopsy-proven IgAN experienced COVID-19) compared with Group non-CoV (44 patients with IgAN without COVID-19), respectively. Compared with Group non-CoV, the intensity of glomerular C4d (p = 0.017) and MAC deposition (p < 0.001) and Gd-IgA1 deposition (p = 0.005) were much stronger in Group CoV. Our finding revealed that for IgAN after COVID-19, mucosal immune responses to SARS-CoV-2 infection may result in the overactivation of systemic and renal local complement system, and increased glomerular deposition of Gd-IgA1, which may lead to renal dysfunction and promote renal progression in IgAN patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Complement system
|
| 650 |
|
4 |
|a Gd-IgA1
|
| 650 |
|
4 |
|a IgA nephropathy
|
| 700 |
1 |
|
|a Wang, Guo-Qin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kong, Ling-Qiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Li-Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Xiao-Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Wen-Rong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Hong-Rui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Hong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 263(2024) vom: 01. Juni, Seite 110232
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:263
|g year:2024
|g day:01
|g month:06
|g pages:110232
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110232
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 263
|j 2024
|b 01
|c 06
|h 110232
|